Novo Nordisk A/S - Stock

Novo Nordisk A/S EBIT 2024

Novo Nordisk A/S EBIT

132.07 B DKK







In 2024, Novo Nordisk A/S's EBIT was 132.07 B DKK, a 26.14% increase from the 104.7 B DKK EBIT recorded in the previous year.

The Novo Nordisk A/S EBIT history

YEAREBIT (undefined DKK)

Novo Nordisk A/S Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Net Income

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Novo Nordisk A/S, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Novo Nordisk A/S from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Novo Nordisk A/S’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Novo Nordisk A/S. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Novo Nordisk A/S’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Novo Nordisk A/S’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Novo Nordisk A/S’s growth potential.

Novo Nordisk A/S Revenue, Profit, and EBIT History

DateNovo Nordisk A/S RevenueNovo Nordisk A/S EBITNovo Nordisk A/S Net Income
2029e533.85 B DKK0 DKK150.38 B DKK
2028e475.8 B DKK232.85 B DKK129.86 B DKK
2027e442.49 B DKK211.38 B DKK121.56 B DKK
2026e409.45 B DKK191.13 B DKK114.36 B DKK
2025e353.78 B DKK161.53 B DKK96.65 B DKK
2024e292.92 B DKK132.07 B DKK78.86 B DKK
2023232.26 B DKK104.7 B DKK83.68 B DKK
2022176.95 B DKK75.67 B DKK55.53 B DKK
2021140.8 B DKK59.36 B DKK47.76 B DKK
2020126.95 B DKK54.6 B DKK42.14 B DKK
2019122.02 B DKK53.68 B DKK38.95 B DKK
2018111.83 B DKK47.24 B DKK38.63 B DKK
2017111.7 B DKK49.28 B DKK38.13 B DKK
2016111.78 B DKK48.97 B DKK37.93 B DKK
2015107.93 B DKK46.96 B DKK34.86 B DKK
201488.81 B DKK35.13 B DKK26.48 B DKK
201383.57 B DKK31.64 B DKK25.18 B DKK
201278.03 B DKK29.47 B DKK21.43 B DKK
201166.35 B DKK22.37 B DKK17.1 B DKK
201060.78 B DKK18.89 B DKK14.4 B DKK
200951.08 B DKK14.93 B DKK10.77 B DKK
200845.55 B DKK12.37 B DKK9.65 B DKK
200741.83 B DKK8.94 B DKK8.52 B DKK
200638.74 B DKK9.12 B DKK6.45 B DKK
200533.76 B DKK8.09 B DKK5.86 B DKK
200429.03 B DKK6.98 B DKK5.01 B DKK

Novo Nordisk A/S stock margins

The Novo Nordisk A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Novo Nordisk A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Novo Nordisk A/S.
  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin


Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Novo Nordisk A/S's sales revenue. A higher gross margin percentage indicates that the Novo Nordisk A/S retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Novo Nordisk A/S's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Novo Nordisk A/S's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Novo Nordisk A/S's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Novo Nordisk A/S. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Novo Nordisk A/S's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Novo Nordisk A/S Margin History

Novo Nordisk A/S Gross marginNovo Nordisk A/S Profit marginNovo Nordisk A/S EBIT marginNovo Nordisk A/S Profit margin
2029e84.6 %0 %28.17 %
2028e84.6 %48.94 %27.29 %
2027e84.6 %47.77 %27.47 %
2026e84.6 %46.68 %27.93 %
2025e84.6 %45.66 %27.32 %
2024e84.6 %45.09 %26.92 %
202384.6 %45.08 %36.03 %
202283.92 %42.76 %31.38 %
202183.2 %42.16 %33.92 %
202083.51 %43.01 %33.19 %
201983.97 %43.99 %31.92 %
201884.25 %42.24 %34.54 %
201784.21 %44.12 %34.14 %
201684.63 %43.81 %33.93 %
201585 %43.51 %32.3 %
201483.6 %39.56 %29.82 %
201383.08 %37.86 %30.13 %
201282.74 %37.77 %27.47 %
201181.03 %33.72 %25.77 %
201080.78 %31.08 %23.7 %
200979.56 %29.24 %21.08 %
200877.81 %27.16 %21.17 %
200776.59 %21.38 %20.37 %
200675.26 %23.54 %16.65 %
200572.82 %23.96 %17.37 %
200472.27 %24.04 %17.27 %

Novo Nordisk A/S Aktienanalyse

What does Novo Nordisk A/S do?

Novo Nordisk A/S is a Danish company specializing in the production of insulin and other diabetes medications. It was founded in 1923 and has its headquarters in Bagsværd, Denmark. Novo Nordisk is the world's largest manufacturer of insulin and one of the key players in the field of diabetes treatment. Novo Nordisk A/S ist eines der beliebtesten Unternehmen auf

EBIT Details

Analyzing Novo Nordisk A/S's EBIT

Novo Nordisk A/S's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Novo Nordisk A/S's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Novo Nordisk A/S's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Novo Nordisk A/S’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Novo Nordisk A/S Stock

How much did Novo Nordisk A/S achieve in EBIT for the current year?

In the current year, Novo Nordisk A/S has achieved an EBIT of 132.07 B DKK.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Novo Nordisk A/S.

How has the EBIT of Novo Nordisk A/S developed in recent years?

The EBIT of Novo Nordisk A/S has increased by 26.144% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Novo Nordisk A/S?

The EBIT of Novo Nordisk A/S is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Novo Nordisk A/S pay?

Over the past 12 months, Novo Nordisk A/S paid a dividend of 14.15 DKK . This corresponds to a dividend yield of about 1.43 %. For the coming 12 months, Novo Nordisk A/S is expected to pay a dividend of 14.94 DKK.

What is the dividend yield of Novo Nordisk A/S?

The current dividend yield of Novo Nordisk A/S is 1.43 %.

When does Novo Nordisk A/S pay dividends?

Novo Nordisk A/S pays a quarterly dividend. This is distributed in the months of September, April, September, April.

How secure is the dividend of Novo Nordisk A/S?

Novo Nordisk A/S paid dividends every year for the past 26 years.

What is the dividend of Novo Nordisk A/S?

For the upcoming 12 months, dividends amounting to 14.94 DKK are expected. This corresponds to a dividend yield of 1.51 %.

In which sector is Novo Nordisk A/S located?

Novo Nordisk A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Novo Nordisk A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Novo Nordisk A/S from 3/26/2024 amounting to 6.4 DKK, you needed to have the stock in your portfolio before the ex-date on 3/22/2024.

When did Novo Nordisk A/S pay the last dividend?

The last dividend was paid out on 3/26/2024.

What was the dividend of Novo Nordisk A/S in the year 2023?

In the year 2023, Novo Nordisk A/S distributed 11.15 DKK as dividends.

In which currency does Novo Nordisk A/S pay out the dividend?

The dividends of Novo Nordisk A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Novo Nordisk A/S stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Novo Nordisk A/S

Our stock analysis for Novo Nordisk A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novo Nordisk A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.